Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Diabetes UK

- PMLiVE

Provention Bio wins PRIME designation for type 1 diabetes prevention drug

Meanwhile J&J partnered Crohn's drug flops in phase 2

- PMLiVE

Vertex eyes type 1 diabetes cure with biotech acquisition

Will acquire Semma Therapeutics for $950m

- PMLiVE

Tiziana joins type 1 diabetes prevention field

Cites potential advantages

- PMLiVE

Type 1 diabetes prevention promise sends Provention Bio soaring

Remarkable results prompt firm to consider regulatory pathway

- PMLiVE

Success for AZ, setback for Sanofi in type 1 diabetes

Forxiga approved as add-on to insulin

- PMLiVE

UCB signs research deal with King’s College London

Company and academic researchers to share one facility

- PMLiVE

Novo Nordisk expands cell therapy R&D, says type 1 diabetes cure a step closer

Company has reached milestone in stem cell therapy as it looks to broaden range beyond diabetes

- PMLiVE

Diabetes UK uses Lego to address diabetes myths

Teams up with Brickabetes to document the highs and lows of living with diabetes

- PMLiVE

Diabetes rates jump by 60% in UK

Comes as new analysis also reveals that 10% of the NHS GP drugs budget spent on the disease

Sanofi reception

Type 1 diabetes market to double to $13.6bn

New treatments will see this growth by 2023, according to GlobalData

- PMLiVE

The rising prevalence of diabetes in Europe

The condition is still an unstoppable epidemic

- PMLiVE

Young diabetes patients in England and Wales receive fewer vital checks

Less than a third with type 1 diabetes receive eight of nine recommended care processes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links